Tackling Empirical Antibiotic Therapy for Ventilator-Associated Pneumonia in Your ICU: Guidance for Implementing the Guidelines

ABSTRACT

Guidelines published jointly by the American Thoracic Society and Infectious Diseases Society of America endorse the practice of appropriate empirical antibiotic therapy for ventilator-associated pneumonia (VAP) and even provide recommendations for specific antibiotics based on whether a patient has risk factors for multidrug-resistant infections. Unfortunately, the current guidelines provide little insight into how a specific institution can best develop a strategy for providing empirical antibiotic therapy. This review article focuses on important steps that should be taken in developing a hospital-specific pathway for the empirical antibiotic treatment of VAP. Consideration should be given to developing a multidisciplinary group to obtain intensive care unit (ICU)-specific antibiograms for the most common causative organisms, real-time minimum inhibitory concentration (MIC) data or MIC distributions from surveillance studies over a representable time frame, and implementing empirical dosage strategies aimed at achieving not only appropriate therapy but also optimal therapy based on pharmacodynamic targets. A proper deescalation strategy will also be vital to managing antibiotic choices and dosages, as well as providing useful recommendations for discontinuation of therapy. Finally, continued feedback of program results is critical to maintaining compliance as well as for reevaluating empirical antibiotic choices.

KEYWORDS

Pneumonia - ventilator - VAP - antibiotic - pharmacodynamics - pathway

REFERENCES

• 1 American Thoracic Society and the Infectious Disease Society of America . Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
• 2 Craven D E, Kunches L M, Killinsky V, Lichtenberg D A, Make B J, McCabe W R. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation.  Am Rev Respir Dis. 1986;  133 792-796
• 3 Chastre J, Fagon J Y. Ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2002;  165 867-903
• 4 Fagon J Y, Chastre J, Hance A J, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay.  Am J Med. 1993;  94 281-288
• 5 Rello J, Ollendorf D A, Oster G et al.. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.  Chest. 2002;  122 2115-2121
• 6 Kollef M H, Silver P, Murphy D M, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality.  Chest. 1995;  108 1655-1662
• 7 Valles J, Pobo A, Garcia-Esquirol O, Mariscal D, Real J, Fernandez R. Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset.  Intensive Care Med. 2007;  33 1363-1368
• 8 Pronovost P J, Miller M R, Dorman T, Berenholtz S M, Rubin H. Developing and implementing measures of quality of care in the intensive care unit.  Curr Opin Crit Care. 2001;  7 297-303
• 9 Berenholtz S M, Milanovich S, Faircloth A et al.. Improving care for the ventilated patient.  Jt Comm J Qual Saf. 2004;  30 195-204
• 10 Isakow W, Kollef M H. Preventing ventilator-associated pneumonia: an evidence-based approach of modifiable risk factors.  Semin Respir Crit Care Med. 2006;  27 5-17
• 11 Murray T, Goodyear-Bruch C. Ventilator-associated pneumonia improvement program.  AACN Adv Crit Care. 2007;  18 190-199
• 12 Gastmeier P, Geffers C. Prevention of ventilator-associated pneumonia: analysis of studies published since 2004.  J Hosp Infect. 2007;  67 1-8
• 13 Health Care Performance Measurement Initiatives—2006. Available at: http://www.jointcommission.org/Physicians/md_pi.htm Accessed November 13, 2007
• 14 Kollef M H, Sherman G, Ward S, Fraser V J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest. 1999;  115 462-474
• 15 Iregui M, Ward S, Sherman G, Fraser V J, Kollef M H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.  Chest. 2002;  122 262-268
• 16 Luna C M, Aruj P, Niederman M S et al.. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia.  Eur Respir J. 2006;  27 158-164
• 17 Rello J, Diaz E. Pneumonia in the intensive care unit.  Crit Care Med. 2003;  31 2544-2551
• 18 Rello J, Sa-Borges M, Correa H, Leal S R, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.  Am J Respir Crit Care Med. 1999;  160 608-613
• 19 Styers D, Sheehan D J, Hogan P, Sahm D F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.  Ann Clin Microbiol Antimicrob. 2006;  5 2
• 20 Nicasio A M, Kuti J L, Nicolau D P. The current state of multidrug-resistant gram-negative bacilli in North America: insights from the Society of Infectious Diseases Pharmacists.  Pharmacotherapy. 2008;  28 235-249
• 21 Beardsley J R, Williamson J C, Johnson J W, Ohl C A, Karchmer T B, Bowton D L. Using local microbiological data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia.  Chest. 2006;  130 787-793
• 22 Green D L. Selection of an empiric antibiotic regimen for hospital-acquired pneumonia using a unit and culture-type specific antibiogram.  J Intensive Care Med. 2005;  20 296-301
• 23 Binkley S, Fishman N O, Larosa L A et al.. Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy.  Infect Control Hosp Epidemiol. 2006;  27 682-687
• 24 Eagye K J, Shore E, Dobkin E, Palter M, Nicolau D P, Kuti J L. Differing epidemiology and resistance patterns of respiratory isolates from three intensive care units within the same institution [abstract K-0259]. In: Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC; American Society of Microbiology 2006: 304
• 25 Clinical and Laboratory Standards Institute (CLSI) .Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data: Approved Guideline. 2nd ed. CLSI document M39–A2 Wayne, PA; Clinical and Laboratory Standards Institute 2005
• 26 Mohr J F, Wanger A, Rex J H. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients.  Diagn Microbiol Infect Dis. 2004;  48 125-130
• 27 Bouza E, Torres M V, Radice C et al.. Direct E-test (AB BIODISK) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia.  Clin Infect Dis. 2007;  44 382-387
• 28 Gillespie E L, Kuti J L, Nicolau D P. When “S” doesn't mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections.  Conn Med. 2005;  69 203-210
• 29 Drusano G L. Antimicrobial pharmacodynamics: critical interactions of “bug and drug.”  Nat Rev Microbiol. 2004;  2 289-300
• 30 Craig W A. Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.  Clin Infect Dis. 1998;  26 1-10
• 31 Turnidge J D. The pharmacodynamics of β-lactams.  Clin Infect Dis. 1998;  27 10-22
• 32 Li J, Turnidge J, Milne R, Nation R L, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.  Antimicrob Agents Chemother. 2001;  45 781-785
• 33 Moore R D, Smith C R, Lietman P S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.  J Infect Dis. 1984;  149 443-448
• 34 Moore R D, Lietman P S, Smith C R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.  J Infect Dis. 1987;  155 93-99
• 35 Preston S L, Drusano G L, Berman A L et al.. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.  JAMA. 1998;  279 125-129
• 36 Freeman C D, Nicolau D P, Belliveau P P, Nightingale C H. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.  J Antimicrob Chemother. 1997;  39 677-686
• 37 Nicolau D P, Freeman C D, Belliveau P P, Nightingale C H, Ross J W, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.  Antimicrob Agents Chemother. 1995;  39 650-655
• 38 Kashuba A D, Nafziger A N, Drusano G L, Bertino J S. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.  Antimicrob Agents Chemother. 1999;  43 623-629
• 39 Kuti J L, Nicasio A M, Shore E, Palter M, Pepe J, Nicolau D P. Outcomes of an empiric antibiogram algorithm (EAA) for ventilator associated pneumonia (VAP) that considers local MIC distributions and pharmacodynamics (PD) [abstract 1093]. 45th Annual Meeting of the Infectious Diseases Society of America San Diego, CA; October 4–7, 2007
• 40 Lacy M K, Lu W, Xu X et al.. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.  Antimicrob Agents Chemother. 1999;  43 672-677
• 41 Wright D H, Brown G H, Peterson M L, Rotschafer J C. Application of fluoroquinolone pharmacodynamics.  J Antimicrob Chemother. 2000;  46 669-683
• 42 Forrest A, Nix D E, Ballow C H, Goss T F, Birmingham M C, Schentag J J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.  Antimicrob Agents Chemother. 1993;  37 1073-1081
• 43 Ambrose P G, Grasela D M, Grasela T H, Passarell J, Mayer H B, Pierce P F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.  Antimicrob Agents Chemother. 2001;  45 2793-2797
• 44 Drusano G L, Preston S L, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.  J Infect Dis. 2004;  189 1590-1597
• 45 Deryke C A, Kuti J L, Nicolau D P. Re-evaluation of current susceptibility breakpoints for gram-negative rods based on pharmacodynamic assessment.  Diagn Microbiol Infect Dis. 2007;  58 337-344
• 46 Deryke C A, Kuti J L, Nicolau D P. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.  Pharmacotherapy. 2007;  27 333-342
• 47 Sun H K, Kuti J L, Nicolau D P. Pharmacodynamics of antimicrobials for the empiric treatment of nosocomial pneumonia: a report from the OPTAMA Program.  Crit Care Med. 2005;  33 2222-2227
• 48 Mattoes H M, Kuti J L, Drusano G L, Nicolau D P. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.  Clin Ther. 2004;  26 1187-1198
• 49 Kim A, Sutherland C A, Kuti J L, Nicolau D P. Optimal dosing of piperacillin/tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?.  Pharmacotherapy. 2007;  27 1490-1497
• 50 Zosyn (piperacillin/tazobactam for injection) package insert. Collegeville, PA; Wyeth Pharmaceuticals 2005
• 51 Ludwig E, Konkoly-Thege M, Kuti J L, Nicolau D P. Optimizing antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian Hospitals.  Int J Antimicrob Agents. 2006;  28 433-438
• 52 Kuti J L, Moss K M, Nicolau D P, Knauft R F. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: Application of pharmacodynamic concepts to meropenem therapy.  Pharmacotherapy. 2004;  24 1641-1645
• 53 Lodise Jr T P, Lomaestro B M, Drusano G L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.  Clin Infect Dis. 2007;  44 357-363
• 54 Rybak M J. The pharmacokinetic and pharmacodynamic properties of vancomycin.  Clin Infect Dis. 2006;  42 S35-S39
• 55 Moise P A, Forrest A, Bhavnani S M, Birmingham M C, Schentag J J. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. .  Am J Health Syst Pharm. 2000;  57(Suppl 2) S4-9
• 56 Moise-Broder P A, Forrest A, Birmingham M C, Schentag J J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.  Clin Pharmacokinet. 2004;  43 925-942
• 57 Sakoulas G, Moise-Broder P A, Schentag J, Forrest A, Moellering R C, Eliopoulus G M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.  J Clin Microbiol. 2004;  42 2398-2402
• 58 Soriano A, Marco F, Martinez J A et al.. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.  Clin Infect Dis. 2008;  46 193-200
• 59 Kuti J L, Kiffer C RV, Mendes C MF, Nicolau D P. Pharmacodynamic comparison of linezolid, teicoplanin, and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.  Clin Microbiol Infect. 2008;  14 116-123
• 60 Hidayat L K, Hsu D I, Quist R, Shriner K A, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.  Arch Intern Med. 2006;  166 2138-2144
• 61 Rello J, Vidaur L, Sandiumenge A et al.. De-escalation therapy in ventilator-associated pneumonia.  Crit Care Med. 2004;  32 2183-2190
• 62 Micek S T, Ward S, Fraser V J, Kollef M H. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia.  Chest. 2004;  125 1791-1799
• 63 Ibrahim E H, Ward S, Sherman G, Schaiff R, Fraser V J, Kollef M H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.  Crit Care Med. 2001;  29 1109-1115
• 64 Kollef M H, Kollef K E. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results.  Chest. 2005;  128 2706-2713
• 65 Chastre J, Wolff M, Fagon J Y et al.. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 2588-2598
• 66 Soo Hoo G W, Wen Y E, Nguyen T V, Goetz M B. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia.  Chest. 2005;  128 2778-2787
• 67 Evans R S, Pestotnik S L, Classen D C et al.. A computer-assisted management program for antibiotics and other antiinfective agents.  N Engl J Med. 1998;  338 232-238
• 68 Dellit T H, Owens R C, McGowan J E et al.. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.  Clin Infect Dis. 2007;  44 159-177